AbbVie has submitted a New Drug Application (NDA) to the FDA for tavapadon, an investigational, oral, once-daily treatment for Parkinson’s disease to be used with or without levodopa, according to a news release published today.

"For many people living with Parkinson's disease, today's oral standard of care isn't effective enough to manage symptoms," Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie, said in the news release.

Parkinson’s is a progressive neurological disorder caused by the death of dopamine-producing neurons in the brain, specifically in the basal ganglia, the area of the brain that controls movement.

Motor symptoms such as shaking, stiffness and difficulty with balance appear when approximately 60 to 80% o

See Full Page